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Colon cancer accounts for more than 10% of all cancer deaths annually. Our genetic evidence from Drosophila and
previous in vitro studies of mammalian Atonal homolog 1 (Atoh1, also called Math1 or Hath1) suggest an anti-
oncogenic function for the Atonal group of proneural basic helix-loop-helix transcription factors. We asked whether
mouse Atoh1 and human ATOH1 act as tumor suppressor genes in vivo. Genetic knockouts in mouse and molecular
analyses in the mouse and in human cancer cell lines support a tumor suppressor function for ATOH1. ATOH1
antagonizes tumor formation and growth by regulating proliferation and apoptosis, likely via activation of the Jun N-
terminal kinase signaling pathway. Furthermore, colorectal cancer and Merkel cell carcinoma patients show genetic
and epigenetic ATOH1 loss-of-function mutations. Our data indicate that ATOH1 may be an early target for oncogenic
mutations in tissues where it instructs cellular differentiation.
Citation: Bossuyt W, Kazanjian A, De Geest N, Van Kelst S, De Hertogh G, et al. (2009) Atonal homolog 1 is a tumor suppressor gene. PLoS Biol 7(2): e1000039. doi:10.1371/
journal.pbio.1000039
Introduction
The Atonal (Ato) proneural transcription factors form a
highly conserved group of key developmental regulators in
multiple neural and neuroendocrine tissues. The mammalian
Ato (CG7508) ortholog, ATOH1 (Ensembl accession number:
ENSG00000172238), is essential for cell fate commitment of
mechanoreceptive Merkel cells in the skin [1] and the
secretory goblet, Paneth, and enteroendocrine cells in the
intestine [2,3] in addition to multiple neuronal lineages [4,5].
The functional conservation between the ﬂy and mammalian
proteins is underscored by the fact that Drosophila ato can fully
rescue the Atoh1 (Ensembl: ENSMUSG00000073043) null
mutant mouse [6].
Genetic analyses in Drosophila [7] suggest that ato regulates
the formation and progression of tumors in ﬂy retina, where
it acts as a master regulator of cell fate speciﬁcation. In
mammals, two aggressive human cancers derive from tissues
where ATOH1 instructs cell fate commitment, namely Merkel
cell carcinoma (MCC) and colorectal cancer (CRC). MCC is a
rare, but very aggressive, neuroendocrine cancer of the skin
with approximately 40% mortality [8]. CRC is a highly
prevalent cancer with high mortality (36%) representing
11% of all cancer deaths annually [9]. Recent studies in colon
cancer cell lines suggest that ATOH1 can inhibit tumor cell
growth in vitro [10]. If the anti-oncogenic function of
Drosophila ato is conserved in its mammalian counterparts,
one would predict that the loss and gain of function of
ATOH1 would enhance and suppress tumor formation,
respectively, in MCC and CRC models. In addition, the
ATOH1 should be subject to loss-of-function mutations in a
signiﬁcant number of human cancer patients.
We tested this prediction in two different mouse models for
colon cancer, as well as human MCC and CRC cell lines. In
addition, we examined the status of the ATOH1 locus in
primary tumor samples from human MCC and CRC patients.
Our data show that loss of ATOH1 strongly enhances the
formation and progression of tumors in mice and human cell
lines. Conversely, gain of ATOH1 function strongly inhibits the
oncogenic phenotypes in human cell lines. Furthermore, we
ﬁnd genetic and epigenetic loss-of-function mutations with
very high frequency in primary human tumors derived from
ATOH1-dependenttissuesandprovidebiochemicalinsightinto
howtheseepigeneticmutationsmayarise.Finally,wedescribea
highly conserved anti-oncogenic molecular signaling pathway
that links ATOH1 activity to the stress sensor Jun N-terminal
kinase (JNK) pathway mediated via cell type–speciﬁc differ-
ential co-option of receptor tyrosine kinases (RTKs). Together
with the genetic analysis in Drosophila [7], these data support a
novel, highly conserved tumor suppressor function for the
Atonal group of transcription factors.
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Loss of Atoh1 Promotes Tumor Formation in Two
Colorectal Cancer Mouse Models
In the mouse, Atoh1 is a master regulator of secretory cell
fate commitment in the intestinal epithelium [2,11]. To
investigate whether Atoh1 plays a role in intestinal tumors,
we analyzed the function of the mammalian ato homolog,
Atoh1, in colon tumorigenesis. We assessed the tumor
susceptibility of mice with an intestine-speciﬁc deletion of
Atoh1 (Atoh1
Dintestine) [3] in two different established mouse
models of CRC.
We ﬁrst treated Atoh1
Dintestine mice with azoxymethane
(AOM), a chemical carcinogen that preferentially induces
colon tumors. We found a signiﬁcant enhancement in polyp
formation in the large intestines of Atoh1
Dintestine compared to
wild-type littermate mice, characterized by increased inci-
dence (33% [4/12] vs. 100% [8/8], p , 0.005; Figure 1A),
multiplicity (0.75 vs. 10.3 polyps/colon, p , 0.0008; Figure 1C),
and size (2.1 vs. 4.1 mm/polyp, p , 0.0004; Figure 1E) when
examined under the dissecting microscope. Histological
analysis of colons from AOM-treated Atoh1
Dintestine mice
Figure 1. Loss of Atoh1 Enhances Tumor Formation in the Mouse Colon
(A) shows the incidence of polyps in AOM-treated mice.
(B) shows the incidence of polyps in the Atoh1
wt and Atoh1
Dintestine mice in an APC
min background.
In (A) and (B), the two-tailed Fisher exact test was used.
(C) Bar graph shows the average number of macroscopically visible polyps (.1 mm) in the colons of AOM-treated Atoh1
wt (WT; n¼9 polyps in 12 mice,
white bars) and Atoh1
Dintestine (n ¼ 82 polyps in 8 mice, black bars).
(D) The average number of polyps in the colons of APC
min (n ¼ 27 polyps in 27 mice) and APC
min; Atoh1
Dintestine (n ¼ 123 polyps in 10 mice).
(E and F) The average maximum diameter of each polyp is shown as a bar graph for Atoh1
wt or Atoh1
Dintestine mice. (E) Comparison of polyp size from
AOM-treated Atoh1
wt and Atoh1
Dintestine mice; and (F) from APC
min and APC
min; Atoh1
Dintestine mice.
For (C–F), the two-tailed Student t-test was used to measure significance. Error bars indicate the standard error of the mean. Double asterisks (**)
indicate p ,0.01; triple asterisks (***) indicate p ,0.001.
doi:10.1371/journal.pbio.1000039.g001
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Author Summary
Like most cancers, colon cancer displays a loss of differentiation, and
the stronger this property, the more aggressive the cancer. This
suggests that the loss of the capacity to differentiate may be a
critical and possibly early event during the formation of these
tumors. The key gene instructing secretory cell fate differentiation in
the epithelium of the colon, namely Atonal homolog 1 (ATOH1), is
highly conserved in flies, mice, and humans. We asked whether
ATOH1 could be a pivotal factor in causing colon cancer in mice and
humans. Our studies show that colon-specific loss of ATOH1 in mice
is sufficient to trigger colon cancer and that the majority of human
colon cancers also have an inactivated ATOH1. Reactivating ATOH1
in cultured human colon cancer cells causes these cells to stop
dividing and to commit suicide. Since reactivation of this epigeneti-
cally silenced gene can be achieved using small chemical
compounds, studying how ATOH1 acts may offer therapeutic
avenues in the future.conﬁrmed these ﬁndings and showed a range of histological
phenotypes, from severely hyperplastic mucosa with embed-
ded multifocal adenomas, to large, highly dysplastic adeno-
mas, with one animal having invasive adenocarcinoma (Figure
2A, 2A9, and 2A99). In contrast, histological examination of
AOM-treated Atoh1
wt littermates showed none with adenom-
atous changes; with all polyp-like structures shown to be gut-
associated lymphoid tissue (GALT; Figures 2B and S1). These
data support the notion that loss of Atoh1 can be an initiating
event in mammalian cancer formation.
In previous work, we found that ablation of Atoh1 leads to
an increase of proliferation but has no effect on apoptosis [3].
We therefore examined proliferation and apoptosis in the
‘‘preneoplastic’’ normal-appearing epithelium within the
colons of AOM-treated Atoh1
wt and Atoh1
Dintestine mice. As in
the Drosophila model, we ﬁnd more proliferation of epithelial
cells in Atoh1
Dintestine crypts compared to nonrecombined wild-
type crypts within the same animals, or compared to crypts
from Atoh1
wt littermates (Figures 2E and S2D–S2F) but no
obvious difference in apoptosis (Figures 2F and S2G–S2I).
We extended our tumor analysis with an independent
genetic mouse model for CRC by crossing Atoh1
Dintestine mice
to APC
min mice (APC: ENSMUSG00000005871), in which Wnt
signaling is constitutively activated [12,13]. APC
min mice
develop spontaneous adenomas primarily in the small
intestine, with only occasional polyps in the colon [14].
Interestingly, Wnt signaling is thought to interact negatively
with ato during sense organ formation in the developing
Drosophila epithelium [15]. Comparing the large intestines of
APC
min; Atoh1
wt mice to APC
min; Atoh1
Dintestine littermates at 16
wk, we ﬁnd signiﬁcantly more polyps in the colons of double-
mutant mice, characterized by increased incidence (52% [14/
27] vs. 100% [10/10], p ,0.007; Figure 1B), multiplicity (1.1 vs.
12.3 polyps/colon, p ,0.0001; Figure 1D), and size (3.3 vs. 4.3
mm/colon, p ,0.0002; Figure 1F). Histological examination
conﬁrmed these polyps as adenomas in both APC
min; Atoh1
wt
and APC
min; Atoh1
Dintestine mice, with two polyps in APC
min;
Atoh1
Dintestine mice having progressed to invasive adenocarci-
noma (Figure 2C and 2D). The polyps in the APC
min;
Atoh1
Dintestine mice originated from the Atoh1 mutant crypts
as indicated by the absence of goblet cells in the polyps
(Figure S3A and S3B).
In summary, thus far, loss-of-function analysis of Atoh1 in
two mouse models of colon tumorigenesis supports a role for
Atoh1 as a key switch in tumor formation and progression.
This role appears to be mediated by increased cell prolifer-
ation in the absence of Atoh1. Importantly, the mouse tumors
lack the secretory cell types that depend on Atoh1 for their
formation. Thus, the role of Atoh1 in tumor formation is likely
linked to its function as a master regulator of differentiation.
Loss of ATOH1 Expression in Primary Human CRC and
MCC Tumors
Given the remarkable evolutionary conservation of ato/
Atoh1 function in cancer development, we decided to analyze
whether loss of the human ortholog, ATOH1, might be
selected for during malignant transformation in human
cancer. To this end, we investigated the role of ATOH1 in
CRC and MCC. In vitro overexpression experiments in CRC
cell lines suggest that ATOH1 gain of function decreases the
population growth potential of CRC cells [10]. Similarly,
expression analysis in MCC cell lines suggests an inverse
correlation between ATOH1 levels and the population
growth of MCC cells (Figure S4A–S4C) [16]. These observa-
tions hint at a potential role for ATOH1 in these cancers.
To test this possibility in vivo in primary human tumors, we
began by asking whether the expression of ATOH1 is down-
regulated in primary tumor samples from 42 CRC and four
MCC patients. As MCC is a very rare cancer, only four
samples were available for analysis. Seventy percent of the
CRC samples show a signiﬁcant decrease of ATOH1 mRNA
expression compared to tissue-matched colon samples from
normal controls as analyzed by quantitative reverse-tran-
scriptase PCR (RT-qPCR), suggesting that loss of ATOH1
expression is a highly common feature of CRC oncogenesis
(Figures 3F and S4). Furthermore, ATOH1 mRNA levels are
signiﬁcantly lower in adenocarcinoma samples compared to
adenomas (t-test: p ¼ 0.017), indicating progressive loss of
ATOH1 expression levels with increasing tumor severity
(Figure 3A). Similarly, in MCC, the two samples with lower
ATOH1 expression levels were derived from the two patients
showing metastases (Figure S5).
CRC and MCC Patients Show Deletions in the ATOH1
Locus
One mechanism to explain loss of gene expression during
oncogenesis is the deletion of the locus, which we tested for
using quantitative PCR on genomic DNA in all 46 patient
samples, one MCC cell line (MCC14.2), and one CRC cell line
(Ht29). At least one deletion in the locus was detected in 57%
of the samples (Figure 3B and 3F). A second primer set
yielded similar results (49% deletion rate, Figure 3B). One
allele was also deleted in both Ht29 and MCC14.2. Com-
parative genomic hybridization (CGH) array experiments [17]
on three samples did not show a deviation of the clones
ﬂanking the ATOH1 locus (Figures S5 and S6), indicating that
the deletions observed in patients are likely to be ATOH1-
speciﬁc microdeletions. When only one copy is deleted,
complete loss of gene function could be achieved by point
mutations in the remaining allele. Sequencing of the ATOH1
open reading frame of 24 samples, however, did not reveal
any mutations in any of the samples (unpublished data).
Together with the loss of ATOH1 mRNA expression in
patients, these results suggest that an epigenetic silencing
mechanism may be involved—a possibility we tested in
further detail.
The ATOH1 Locus Is Methylated in CRC and MCC Patients
To address a putative epigenetic transcriptional silencing
mechanism, we began by asking whether transcription could,
in principle, be initiated from the ATOH1 locus in cancer
cells. Drosophila ato and mouse Atoh1 are both known to be
autoregulatory [18,19]. This provides the opportunity to test
whether transcription could be activated from the ATOH1
locus by ATOH1 itself in normal versus cancer cells. We took
advantage of expressing the mouse ortholog in human cells to
distinguish the expression of endogenous ATOH1 from that
of Atoh1. For the tests in human cancer cell lines, we used the
MCC14.2 cell line, which is derived from MCC and has
strongly reduced expression of ATOH1. Surprisingly, Atoh1
overexpression failed to activate endogenous human ATOH1
expression in the MCC14.2 cell line (Figure 3C), despite the
virtually complete conservation of the two proteins. This may
be due to a key difference between the two proteins, or to a
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ATOH1 Is a Tumor SuppressorFigure 2. Increased Proliferation Contributes to Tumorigenesis in Atoh1
Dintestine Colon
(A) Hematoxylin and eosin staining of a representative adenoma in AOM-treated Atoh1
Dintestine colon (53 magnification). The section is in the rectal
region and is characterized by cystic structures with severe crypt hyperplasia with multifocal embedded adenomas and severe lymphocyte infiltration of
the submucosa. (L, lumen; M, muscle). (A)9 and (A)99 show higher magnification (203) of two areas of the adenoma, indicating the aberrant branched
crypt structures that are imbedded in the submucosa.
(B) The colons of AOM-treated Atoh1
wt mice showed large GALT (highlighted by arrows) that were macroscopically counted as polyps. Magnification is
53. Note the relative size of the GALT compared to adjacent normal-appearing crypts.
(C) Histological analysis of colon in APC
min.
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ATOH1 Is a Tumor Suppressor(D) Histological analysis in APC
min; Atoh1
Dintestine mice show highly dysplastic adenomas with cystic structures and lymphocyte infiltration.
(E) Proliferation was measured by determining the percentage of BrdU-positive epithelial cells in AOM-treated Atoh1
wt and Atoh1
Dintestine normal-
appearing colonic crypts. The white bar represents crypts from Atoh1
wt mice; the gray bar represents nondeleted Atoh1
wt crypts, and the black bar
Atoh1-null crypts in Atoh1
Dintestine mice.
(F) Apoptosis was measured by determining the percentage of cleaved caspase-3 (c-Caspase 3)-positive epithelial cells in AOM-treated Atoh1
wt and
Atoh1
Dintestine normal-appearing colonic crypts. Bar shading indicates crypt genotype as in (E).
For each graph in (E and F), the two-tailed Student t-test was used to measure significance: a single asterisk (*) indicates p , 0.05; double asterisks (**)
indicate p , 0.01. Error bars indicate the standard error of the mean.
doi:10.1371/journal.pbio.1000039.g002
Figure 3. Loss of ATOH1 Expression and Genomic Deletions in CRC Patient Samples
(A) ATOH1 expression normalized to GADPH and control colon samples: ATOH1 expression is lower in tumor compared to control samples. Additionally,
adenocarcinomas have significantly lower ATOH1 expression than adenomas. Box plot indicating 25–75 percentiles, central line indicates the median,
red cross indicates the mean. Error bars indicate next data point. Outliers are represented as dots. Double asterisks (**) indicate p , 0.01 (t-test).
(B) Deletions in the ATOH1 locus. Upper dashed line indicates the upper limit of single-deletion detection set at 0.70 of the ratio of ATOH1 locus to
control locus. White and gray bars indicate different primer sets.
(C) Endogenous ATOH1 expression in different MCC14.2-derived cell lines and human keratinocytes (HK) in response to Atoh1 expression.
(D) Detection of methylation at the ATOH1 locus using pull-down assay of methylated DNA. Bands in ‘‘M-CpG pulldown’’ indicate positive for ATOH1
methylation. ‘‘Input’’ shows DNA input before the pull-down. Samples were processed blindly. Internal methylated and unmethylated controls are
shown in the last four lanes.
(E) Inhibition of methyltransferase activity with 5-aza-deoxycytosine for 7 d leads to an increase of ATOH1 expression in the Ht29 cell line. Error bars
indicate the standard deviation.
(F) Graph representing observations on the genomic and mRNA levels. First column: percentage of patients showing deletions or duplications (black:
deletions, gray: two copies, and white: duplications). Second column: percentage of patients showing methylation using the pull-down of methylated
DNA assay (black: methylated, and white: not methylated). Third column: mRNA expression of CRC samples versus control colon (black: low expression,
grey: normal expression, and white: high expression).
doi:10.1371/journal.pbio.1000039.g003
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ATOH1 Is a Tumor Suppressorpossible disruption of the autoregulatory loop during onco-
genesis. To test whether Atoh1 can activate ATOH1 expres-
sion in normal noncancerous skin cells, we transduced
normal human primary keratinocytes with an Atoh1 expres-
sion vector and tested the expression of endogenous ATOH1
40 h after lentiviral transduction. In contrast to the cancer
cell lines, endogenous ATOH1 is up-regulated 38-fold by
Atoh1 (Figure 3C). This indicates that the expressability of
the ATOH1 locus is inhibited during oncogenesis.
Genomic database searches show that all known ATOH1
orthologs, from human to Drosophila, reside in a CpG island
covering at least the promoter and the transcription start site,
suggesting that CpG methylation may be a mechanism of
ATOH1 loss of function. We therefore assayed all patient
samples and both cell lines for ATOH1 methylation using
three independent assays: pull-down of methylated DNA,
methylation-sensitive restriction digest, and methylation-
speciﬁc PCR for bisulﬁte DNA modiﬁcation. We found that
up to 81% of the patients, as well as both cell lines, show
methylation of the ATOH1 locus in both the coding sequence
and the promoter sequences directly upstream of the ATG. In
contrast, none of the control samples show ATOH1 methyl-
ation (Figures 3D, 3F, and S7A–S7C). This suggests that
methylation is likely causal to the transcriptional silencing of
the locus during oncogenesis as this is accompanied by lower
ATOH1 expression. In a few cases, however, the correlation
was not observed. In two cases (samples 27 and 30), this may
be due to the presence of a putative duplication, which is yet
to be methylated. Alternatively, but not exclusively, it may be
due to heterogeneity of the degree of methylation in different
cells comprising the tumor samples analyzed. To provide
evidence that methylation silences the ATOH1 locus, we
inhibited DNA methyltransferases (Dnmts) with 5-azadeox-
ycytidine in the Ht29 cell line. This results in an approx-
imately 8-fold increase in ATOH1 expression (Figure 3E).
Thus, the ATOH1 locus is methylated in cancer patients and
derived cell lines, and this methylation can be reversed,
resulting in the transcriptional reactivation of the locus. The
autoregulatory function of ATOH1 combined with the
methylation of its regulatory sequences might hint to the
involvement of ATOH1 in the silencing of its own promoter.
To gain some insight into whether this may indeed be the
case, we asked whether Atoh1 can physically interact with
Dnmt proteins. We tested the binding of Atoh1 to Dnmt1
(ENSG00000130816), Dnmt3a (ENSG00000119772), and
Dnmt3b (ENSG00000088305) using GST pull-down assays.
We ﬁnd that Atoh1 binds to all three Dnmts. This is further
supported by the ability of GST-Atoh1 to pull down DNA
methyltransferase activity from nuclear extracts, similar to
the positive control (EED: embryonic ectoderm development,
ENSG00000074266) [20]. Focusing on Dnmt1, the mainte-
nance DNA methyltransferase, we conﬁrmed this observation
using coimmunoprecipitation experiments in 293T cells
transfected with HA-tagged Atoh1. Lastly, mapping experi-
ments identiﬁed several regions of Dnmt1 as mediating the
association with Atoh1 (Figure S8A–S8D).
In summary, deletions and epigenetic silencing via meth-
ylation combine to cause loss-of-function mutations of the
human ATOH1 locus in primary human cancers. Together
with loss-of-function evidence in ﬁve independent cancer
models in human cells, Drosophila, and mouse, these data
strongly support a role for the Ato/ATOH1 transcription
factors as key modulators of oncogenic transformation.
ATOH1 Functions via JNK-Dependent Inhibition of the Cell
Cycle and Induction of Apoptosis
To better understand the role that ATOH1 plays in cancer,
we sought to determine the molecular mechanism by which it
acts to suppress the formation and progression of tumors.
Gain- and loss-of-function analyses point to Atoh1-dependent
regulation of proliferation in mouse colon tumors (Figures 2E
and S3D–S3F). Analysis of the role of Drosophila ato in ﬂy
retinal tumors [7] shows that this function is mediated by the
JNK signaling pathway. We hypothesized that the Ato-JNK-
p21 pathway may mediate the tumorigenic phenotype in our
mouse models of CRC as well. If loss of ATOH1 were indeed
an initiating event in tumor formation, we reasoned that the
effects of Atoh1 function would have to be detectable in
preneoplastic tissue as this is where oncogenesis begins. We
therefore ﬁrst examined the expression levels of Atoh1,
Cdkn1a (p21, ENSG00000124762), Cdkn1b (p27,
ENSG00000111276), and Cdkn1c (p57, ENSG00000129757)
and the JNK target cJun (ENSG00000177606) in colon crypts
isolated from Atoh1
wt and Atoh1
Dintestine mice (Figure 4A). We
observe a 6.8-fold reduction in Atoh1 expression and an
approximately 2.8-fold reduction in expression of all three
Cdkn1 isoforms in colon crypts from Atoh1
Dintestine mice. We
also observe a similar reduction in cJun mRNA levels. We
further examined the Ato-JNK-Cdkn1 pathway by immuno-
blotting proteins from colon polyps and normal-appearing
colon tissue from APC
min/þ; Atoh1
wt and APC
min/þ; Atoh1
Dintestine
mice. Colon polyps show higher levels of cJun and p21
waf
protein compared to normal colonic tissue. Importantly,
however, we ﬁnd a reduction in cJun levels in APC
min/þ;
Atoh1
Dintestine polyps compared to APC
min/þ; Atoh1
wt polyps,
consistent with the mRNA analysis showing less cJun (Figure
4B). Importantly, we ﬁnd a reduction in p27 protein and a
trend toward less p21 in Atoh1-mutant colon tissues and
polyps, consistent with our analysis of mRNA levels (Figure
4B). We also ﬁnd a speciﬁc reduction in pJNK1 levels
(Figure 4C) in APC
min/þ; Atoh1
wt versus APC
min/þ;
Atoh1
Dintestine tissues, in agreement with earlier reports that
JNK1 (MAPK8: ENSG00000107643) may have anti-oncogenic
activity in the mouse intestine [21], whereas JNK2 (MAPK9:
ENSG00000050748) deﬁciency enhances tumorigenesis in
other epithelia [22]. Finally, we examined the pattern of
JNK activation in the colon of Atoh1
wt and Atoh1
Dintestine mice,
and observe identical numbers of pJNK1/2-positive cells in
Atoh1-null compared to control crypts (Figure S9). Together
with western blot analysis demonstrating selective reduction
in pJNK1, but not pJNK2, our data suggest that the level of
pJNK1 in individual crypt cells is decreased upon loss of
A t o h 1 .T h e s ed a t aa r ec o n s i s t e n tw i t hap r e n e o p l a s t i c
function of Atoh1 in regulating proliferation, by a JNK-
dependent induction of cell cycle inhibitors.
Next we asked whether the molecular mechanism of
ATOH1 function in human cancer is similar to the mouse.
We took advantage of several established MCC cell lines
[23,24] with either high ATOH1 expression (MCC1 and MCC6,
derived from less aggressive tumors) or low ATOH1 expres-
sion (MCC13, MCC14.2, and MCC26, derived from highly
aggressive metastatic tumors; Figure S4A and S4C). We ﬁnd
that the growth rate of cell lines, measured as their doubling
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ATOH1 Is a Tumor Suppressortime, correlates inversely with levels of ATOH1 expression
(Figure S4B). To determine whether the reduction in ATOH1
levels might be causal to decreased doubling time, we
restored ATOH1 function by creating stable cell lines
expressing Atoh1 using lentiviral vectors (Figure 5A and 5B).
Stable Atoh1-expressing cell lines (MCC14.2-Atoh1.1a,
MCC14.2-Atoh1.1b, MCC14.2-Atoh1.2a, and MCC14.2-
Atoh1.2b) have a signiﬁcantly slower population doubling
time compared to control cell lines (MCC14.2 and MCC14.2-
GFP; p ,0.0001; Figure 5C). To assess whether this increase in
doubling time reﬂects decreased malignancy, we tested these
cell lines for growth in soft agar. Cell lines with high levels of
Atoh1 expression display a marked decrease in growth in soft
agar compared to control cell lines (Figure 5D, p , 0.001).
The change in population doubling time could be due to a
slower cell cycle, an increased apoptotic rate, or both.
Although the distribution of cells in the cell cycle appears
unaltered (Figure S10A), the speed of the cell cycle is 25%
lower in Atoh1-expressing cells, as assayed by BrdU pulse-
chase experiments (Figure 5E, p ,0.01).
In addition to slower proliferation, we ﬁnd a speciﬁc and
strongincreaseinapoptoticcelldeath,asmeasuredbyannexin-
Vandcleavedcaspase-3(ENST00000308394),inMCC(MCC14.2
series) and CRC (Ht29) cell lines transduced or transfected with
Atoh1 (Figures 6A, 6B, and S10B). This increase in cell death is
mediated by the intrinsic apoptosis pathway, as suggested by
enhanced caspase-9 (ENST00000333868) cleavage (Figure 6A
and 6B).
Data from mouse models indicate an involvement of JNK-
mediated regulation of cell proliferation for the tumor
suppressor effect of Atoh1. To assess whether the same
mechanisms are operating in human cancer, we tested the
Figure 4. JNK Pathway Influenced by Atoh1
(A) Gene expression analysis in colon crypts from Atoh1
Dintestine and Atoh1
wt mice. Quantitative RT-PCR was used to assess gene expression in isolated
colon crypts. The ratio of gene expression is shown, in which negative numbers indicate reduced expression in Atoh1
Dintestine crypts. t-tests determined
p-values shown for each gene.
(B) Western analysis of p27
kip, p21
waf1, and c-JUN in APC
min; Atoh1
wt, and APC
min; Atoh1
Dintestine colonic tissues and polyps. Representative colonic tissue
and polyp lysates of APC
min; Atoh1
wt, and APC
min; Atoh1
Dintestine were used for western analysis of p27
kip, p21
waf1, and c-JUN. Actin was used a loading
control. p21
waf1 was significantly up-regulated in polyps compared to nonneoplastic colon tissue. c-Jun protein levels were significantly reduced in
colonic polyps upon Atoh1 loss. p27 is down-regulated in preneoplastic colonic tissue upon loss of Atoh1. Quantifications are shown in Figure S12A–
S12C.
(C) Representative tissues were used for Western analysis of phosphorylated JNK1 and JNK2. Total JNK1 and JNK2 are shown as control. Actin loading
control is shown below. pJNK1, but not pJNK2, was significantly reduced in colon tissue from Atoh1
Dintestine compared to Atoh1
wt mice. Quantifications
are shown in Figure S12D1–S12D29.
doi:10.1371/journal.pbio.1000039.g004
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ATOH1 Is a Tumor Suppressorexpression levels of the caspase-3 and caspase-9, p21
waf1, and
p-JNK in MCC and CRC cells lines. We note a clear and
speciﬁc up-regulation of p21
waf1 and p-JNK levels upon Atoh1
expression (Figures 6A, 6B, and S10C–S10H). Similarly,
transfection of wild-type Drosophila Ato results in the up-
regulation of cleaved caspase-3, p21
waf1, and p-JNK (Figure
6C), in contrast to a null-mutant form of the protein that
completely fails to bind DNA [25], indicating the conserva-
tion and speciﬁcity of the Ato/Atoh1 effect.
Next, we tested the expression of these proteins in a loss-
of-function setting. We generated and expressed the tran-
scriptional repressor form of ATOH1 by fusing it to the
engrailed repressor domain (ATOH1
ERD) [26], which specif-
ically inhibits the Atoh1-induced effects on MCC cell lines
(Figure 6D). In the MCC1 cell line, which shows higher
endogenous ATOH1 expression compared to MCC14.2
(Figure S4C), expression of ATOH1
ERD leads to a down-
regulation of p21
waf1 and p-JNK as well as inhibition of
caspase-3 cleavage (Figure 6E).
In summary, gain- and loss-of-function studies in mouse
Figure 5. ATOH1 Suppresses Growth by Interfering with the Cell Cycle
(A) Constructs used for creating lentiviral and transfection vectors.
(B) Western blot analysis for Atoh1 and chromogranin on untransduced MCC14.2 cells (lane 1), GFP-transduced MCC14.2 cells (lane 2), and two
independently derived MCC14.2 cell lines transduced with Atoh1-IRES-eGFP (lane 3: MCC14.2-Atoh1.1a, and lane 4: MCC14.2-Atoh1.2a). Quantifications
in Figure S12E and S12F.
(C) Doubling time in hours for MCC14.2 (lane 1), MCC14.2-GFP (lane 2), and four lines independently transduced with Atoh1-IRES-eGFP (lanes 3–6:
MCC14.2-Atoh1.1a, MCC14.2-Atoh1.1b, MCC14.2-Atoh1.2a, and MCC14.2-Atoh1.2b, respectively).
(D) Assay for growth in soft agar. Colonies per view with a 103 lens, lane 1: MCC14.2, lane 2: MCC14.2-GFP, lane 3: MCC14.2-Atoh1.1a, and lane 4:
MCC14.2-Atoh1.2a. Error bars indicate the 25th and 75th percentiles.
The triple asterisks (***) in (C and D) indicate a significant difference from MCC14.2 (t-test: p , 0.001).
(E) Percentage of cells positively labeled for BrdU and past S-phase in a BrdU pulse-chase experiment; double asterisks (**) indicate p , 0.01 (t-test).
doi:10.1371/journal.pbio.1000039.g005
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ATOH1 Is a Tumor Suppressorcolon cancer models and human cancer cells support a
conserved antitumor function for ATOH1 mediated by JNK
and p21.
ATOH1 Activates RTK Expression in Human Cancer Cells
How does ATOH1 expression lead to JNK activation in
cancer cells? ATOH1 and its orthologs are known to exert
their developmental functions by modulating Notch; Atonal
orthologs inhibit Notch signaling to induce differentiation
during development, whereas Notch inhibits ato expression
by its target gene Hes1 (ENSG00000114315) [27–29]. Notch
signaling has also been described to be upstream of JNK [30].
However, three lines of evidence suggest that the Atoh1-
mediated effects are not Notch-dependent. First, Atoh1
expression levels do not inﬂuence expression of HES1,a
Notch signaling target gene (Figure S11A). Second, we do not
detect cleaved intracellular Notch in the MCC14.2 cell line,
which expresses low levels of ATOH1 (Figure S11B). Finally,
Figure 6. ATOH1 Leads to Activation of Apoptosis and Expression of p21
waf1
(A) Western blot analysis for p21
waf1, cleaved caspase-3, cleaved caspase-9, and phosphorylated JNK of lysates of MCC14.2 cells, MCC14.2-GFP, and two
MCC14.2 cell lines transduced with Atoh1-IRES-eGFP (MCC14.2-Atoh1.1a and MCC14.2-Atoh1.2a). The corresponding actin loading controls are shown
under each blot. Quantifications are shown in Figure S12G–S12J.
(B) Western blot analysis for p21
waf1, cleaved caspase-3, cleaved caspase-9, and p-JNK of lysates of Ht29 cell line transfected with pCLIG-eGFP (left lane)
or pCLIG-Atoh1-IRES-eGFP (right lane); actin loading controls are shown under the respective blots. Quantifications are shown in Figure S12K–S12N.
(C) The molecular changes are specific to functional ato: western blot of lysates of Ht29 cells transfected with CMV-ato, CMV-ato
1, or empty vector. Actin
loading controls are shown below the respective blots. Quantifications are shown in Figure S12O–S12Q.
(D) Graph expressing ratio of cell numbers of MCC14.2-derived cell lines transfected with pMSCV-ATOH1
ERD-IRES-eGFP versus cell number of cell lines
transfected with pMSCV-IRES-eGFP (vector). Statistical analysis was done using t-test under different conditions compared to MCC14.2. Single asterisk (*)
indicates p , 0.05; double asterisks (**) indicate p , 0.01.
(E) MCC1 cells transfected with dominant-negative ATOH1
ERD fusion (lanes 1 and 2) and with empty vector control (lanes 3 and 4). Western blot analysis
for p21
waf1, phosphorylated JNK, and cleaved caspase-3 on lysates of MCC1 cell line. The actin loading control of each blot is shown below.
Quantifications are shown in Figure S12R–S12T.
doi:10.1371/journal.pbio.1000039.g006
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secretase [31] has no effect on the growth of MCC cells
(Figure S11C). Other known upstream activators of JNK are
RTKs [32]. As Atoh1 is a transcription factor, we checked
mRNA expression of all 90 human RTKs upon Atoh1
expression in both the MCC14.2 and the Ht29 cell line
compared to control cells. We observed a signiﬁcant and
speciﬁc Atoh1-dependent up-regulation of Neurotrophic
tyrosine kinase receptor type 1 (NTRK1: ENSG00000198400),
a hallmark for differentiation in Merkel cells [33,34] in
MCC14.2, and of FGF receptors in Ht29 (Figure S11D). The
increase in NTRK1 expression in MCC14.2 seen on the
mRNA level was conﬁrmed using RT-qPCR (Figure S10E). We
also observed elevated NTRK1 levels in the endogenously
ATOH1-expressing MCC1 cells (Figure S10E). This was
accompanied by higher protein levels of both the NTRK1
receptor and one of its ligands, Neurotrophin-3 (NT3:
ENSG00000185652; Figure S10E–S10H), also a marker for
Merkel cell differentiation. Therefore, Ato gain of function
results in tumor type–speciﬁc elevation of RTK levels.
ATOH1 Functions by RTK-Mediated JNK Activation
To test whether the RTKs may be functionally linked with
ATOH1, we incubated the various MCC cell lines with K252a,
a narrow-speciﬁcity RTK inhibitor (NTRK, FGFR, PDGFR,
and IGFR) [35–37]. This results in a dose-dependent decrease
in doubling time of the MCC14.2-derived, Atoh1-expressing
cell lines, indicating that the Atoh1-induced change in
doubling time is RTK-dependent (Figure 7A). In addition,
the induction of apoptosis by Atoh1 in the MCC14.2 and the
Ht29 cell line is blocked by RTK inhibition (Figure 7B and
7C). These effects are accompanied by RTK inhibitor–
dependent decrease in the expression of p21
waf1 and p-JNK
(Figure 7D), suggesting that both p21
waf1 and p-JNK are
downstream effectors of Atoh1-induced RTK signaling. Next,
we asked whether p-JNK is required for p21
waf1 up-regulation
and apoptosis by treating MCC cells with SAPK Inhibitor II, a
Figure 7. Molecular Mechanism for ATOH1 Function
(A–D) show that ATOH19s anti-oncogenic function acts through receptor tyrosine kinases. (A) Doubling times in hours of MCC14.2 and MCC14.2
transduced with eGFP (lane 2) or Atoh1-IRES-eGFP (lanes 3 and 4) with increasing concentrations of K252a. (B) AnnexinV-positive signals normalized to
transfected MCC14.2 cells (GFP). Cells transduced with eGFP (lanes 1 and 2) and Atoh1-IRES-eGFP (lanes 3 and 4) with 0.33 lM K252a (lanes 2 and 4) or
DMSO as a control (lanes 1 and 3). The double asterisks (**) indicate significant difference from GFP transfected without K252a (t-test: p , 0.05). (C)
AnnexinV-positive signals normalized to transfected Ht29 cells (GFP). Cells transfected with eGFP (lanes 1 and 2) and Atoh1-IRES-eGFP (lanes 3 and 4)
with 0.33 lM K252a (lanes 2 and 4) or DMSO as control (lanes 1 and 3). The double asterisks (**) indicate significant difference from GFP transfected
without K252a (t-test: p , 0.05). (D) Inhibition of RTKs inhibits p21
waf1 expression and JNK phosphorylation. Western blot analysis for p21
waf1 and pJNK
of MCC14.2 (lanes 1 and 5), MCC14.2 transduced with eGFP (lanes 2 and 6), and two MCC14.2-derived cell lines transduced with Atoh1-IRES-eGFP (lanes
3, 4, 7, and 8) with 0.3 lM K252a (lanes 1–4) and with DMSO as a control (lanes 5–8). Actin loading controls are shown below each blot. Quantifications
are shown in Figure S12U and S12V.
(E) JNK regulates apoptosis and p21
waf1 expression. Western blot analysis for p21
waf1 and cleaved caspase-3 of MCC14.2 (lanes 1 and 5), MCC14.2
transduced with eGFP (lanes 2 and 6), and two MCC14.2-derived cell lines transduced with Atoh1-IRES-eGFP (lanes 3, 4, 7, and 8) with 1 lM JNK inhibitor
(lanes 1–4) and with DMSO as a control (lanes 5–8). Actin loading control is shown below the blots. Phospho-JNK (P-JNK) blot shows the effect of the
JNK inhibitor on JNK phosphorylation status Quantifications are shown in Figure S12W–S12Y.
(F) Relative cell numbers (the number of Tam67-transfected cells divided by the number of mock-transfected cells) for MCC14.2 and MCC14.2
transduced with eGFP (lane 2) or Atoh1-IRES-eGFP (lanes 3 and 4) with dominant-negative c-jun (TAM67).
doi:10.1371/journal.pbio.1000039.g007
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ATOH1 Is a Tumor Suppressorspeciﬁc JNK inhibitor [38]. We observed a decrease in the
Atoh1-induced expression of p21
waf1 and cleaved caspase-3
(Figure 7E). Similarly, transfection of dominant-negative c-jun
(TAM67) [39] leads to a signiﬁcant increase in cell number
compared to mock-transfected cells (t-test: p ¼ 0.04),
speciﬁcally in the MCC14.2-Atoh1.2a, which has high Atoh1
expression levels (Figure 7F).
In summary, taken together, evidence from mutation
analysis in human patients, as well as gain- and loss-of-
function analysis in mouse and human cells, support a model
(Figure 8) in which ATOH1 modulates JNK activity, possibly
via co-option of context-speciﬁc RTK signaling, to induce
apoptosis and up-regulate p21
waf1 expression, keeping tumor
growth in check. Loss-of-function mutations in ATOH1
prevent JNK-mediated apoptosis and p21-mediated cell cycle
arrest, leading to enhanced tumor progression.
Discussion
Our data support an evolutionarily conserved tumor
suppressor role for ATOH1 in CRC and MCC. Loss of ATOH1
promotes tumor formation and progression, and mutations
in the ATOH1 locus are found with relatively high frequency.
Given the high deletion and methylation rate of ATOH1 in
human tumor samples, loss of ATOH1 function is likely to be
an early event in these tumors. We therefore propose that
ATOH1 acts as a key switch regulating the transformation of
pre-oncogenic epithelia to neoplastic and metastatic tumors.
Genetic analysis of the function of Drosophila ato in ﬂy eye
tumor suggests that its anti-oncogenic function is linked to its
activity as a regulator of cell fate commitment and differ-
entiation [7]. This is similar to what we observe in the
different mouse models, where the adenomas and adenocar-
cinomas do not contain secretory cells (Figure 2) [3].
Interestingly, this also appears to be the case in human
cancer, where the majority of human CRCs do not contain
differentiated secretory cells. The loss of ATOH1 in most
human CRC patients likely explains this observation. In
addition, cell type–speciﬁc RTK differentiation genes are up-
regulated upon overexpression of Atoh1 in CRC and MCC cell
lines. Importantly, these markers of differentiation are
necessary for the anti-oncogenic effect of ato/ATOH1.
It is tempting to speculate that in other tissues, similar loss
of differentiation factors is involved in oncogenesis. In this
sense, the loss of differentiation factors has already been
implicated in late stages of tumor progression as with GATA-
3 (ENSG00000107485) in breast cancer [40]. Although loss of
GATA-3 in early tumor leads to an inhibition of tumor
formation, loss of GATA-3 in later stages leads to the
acquisition of metastatic potential. We, therefore, wonder
whether loss of other differentiation factors, perhaps bHLH
proteins, might play a role in earlier stages of breast cancer
development.
Tumor suppressor genes are deﬁned by the fact that (1) loss-
of-function mutations make the cells more prone to malig-
nant transformation, (2) overexpression leads to inhibition of
the malignant phenotype, and (3) spontaneous somatic
mutations are found in patients with cancer. ‘‘Classical tumor
suppressor genes,’’ such as p53 (ENSG00000141510), are
special in the sense that when mutated, the cell is more prone
to accumulate additional mutations, and thus actively drive
malignant progression as opposed to just ‘‘taking away the
Figure 8. Schematic Representation of the Potential Mechanism of ATOH19s Function as a Tumor Suppressor
In preneoplastic tissue, Atoh1 keeps malignant transformation in check in a JNK-dependent mechanism by the induction of apoptosis and the inhibition
of cell cycle progression. When Atoh1 is lost due to deletion or methylation, these brakes on oncogenesis fail, and malignant transformation can
progress.
doi:10.1371/journal.pbio.1000039.g008
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ATOH1 Is a Tumor Suppressorbrakes’’ [41]. It is notable that ato/Atoh1 shows most of the
hallmarks of a tumor suppressor gene. Because silencing of
ato/Atoh1 is not sufﬁcient to drive oncogenesis, we suggest that
ato/Atoh1, and similar genes, are important brakes on
malignant transformation. Therefore, the role that differ-
entiation factors might play as key switches in malignant
transformation in different tissues is not different from the
classical deﬁnition of tumor suppressor in a functionally
relevant sense.
The RTK and JNK signaling pathways, which are essential
for Atoh1’s tumor suppressor activity, have been suggested as
context-dependent oncogenes or tumor suppressors [42]. Our
data indicate that Atoh1 is important in deciding this context
by the up-regulation of cell type–speciﬁc RTKs. The
activation and co-option of RTK and JNK signaling by Ato/
ATOH1 in this context suggests that the status of differ-
entiation of the tumor-initiating cell may be the key
determinant of the speciﬁc role of various signaling pathways
in cancer. This may have important clinical implications:
treatment of CRC or MCC patients with RTK or JNK
inhibitors might have an adverse effect on tumors where
ATOH1 is still expressed.
In this medical context, our data suggest that screening for
ATOH1 expression, deletion, and methylation may be a useful
diagnostic tool for early detection and treatment decision of
MCC and CRC. Similarly, treatment of CRC and MCC
patients whose tumors show epigenetic silencing of ATOH1
with DNA methyltransferase inhibitors might prove a power-
ful avenue for therapy, because it appears to be sufﬁcient to
restore ATOH1 expression and induce cancer cell death.
Furthermore, such treatment in combination with Notch
inhibitors may enhance re-expression of the ATOH1-driven
differentiation program [43,44] and synergistically inhibit
cancer growth. Therefore, elucidation of the basic mecha-
nisms of ato/ATOH1 function, as well as their target genes and
interacting proteins, might offer potential avenues for future
therapeutic intervention.
Materials and Methods
Cloning of ATOH1
ERD expression construct. The ATOH1 open
reading frame was PCR ampliﬁed and fused in frame with the
engrailed repressor domain after XhoI restriction digest. This fusion
product was then blunt ligated in the MSCV-IRES-GFP vector
(Clontech), giving rise to the MSCV-ATOH1
ERD-IRES-GFP construct.
Mouse models and treatments. Atoh1
Dintestine mice are a conditional
deletion of Atoh1 and are described in more detail elsewhere [3,45].
These mice were generated using the loxP/cre system in which Cre-
mediated deletion of Atoh1 is mosaic and is restricted to the distal
ileum and large intestine (80%–90% deletion). APC
min mice were
purchased from The Jackson Laboratory and mated with Atoh1
Dintestine
mice to generate APC
min; Atoh1
Dintestine mice. Eight-week-old male
Atoh1
wt and Atoh1
Dintestine littermates were injected intraperitoneally
with AOM (Midwest Research Institute of the National Cancer
Institute’s chemical carcinogen repository) at 10 mg/kg body weight.
AOM was injected weekly for a total of six injections, and the mice
were sacriﬁced 20 wk after the ﬁrst AOM injection. Two hours prior
to sacriﬁce, mice were injected with 50 mg/kg BrdU. The large
intestine was isolated and ﬂushed with PBS and then ﬁxed in 10%
buffered formalin at room temperature for 16–24 h. Colons were
placed in 70% ethanol before macroscopic analysis of polyps, and
then embedded into parafﬁn blocks. Similarly, 16–19-wk-old APC
min
and APC
min; Atoh1
Dintestine colons were isolated and ﬁxed as for the
AOM-treated colons. For macroscopic analysis, the position and
diameter (millimeters) of each polyp were recorded using a dissecting
microscope. The protocol for use of animals was approved by the
Cincinnati Children’s Hospital Institutional Animal Care and Use
Committee.
Immunohistochemistry and microscopic analysis. The colons were
imbedded in parafﬁn blocks and sectioned for hematoxylin and eosin
staining by the University of Cincinnati pathology core facility.
Tumor phenotypes were determined as in Boivin et al. (2003) [46].
Parafﬁn-embedded colons of AOM-treated mice were sectioned at 5
lm and used for BrdU and cleaved caspase-3 staining. Mouse anti-
BrdU antibodies were obtained from the Developmental Studies
Hybridoma Bank maintained by the Department of Biological
Sciences of the University of Iowa. The sections were de-parafﬁnized,
rehydrated, and antigen retrieval was performed in citric acid buffer
(pH ¼ 6) using a microwave. Endogenous peroxidase activity was
blocked with hydrogen peroxide/methanol solution, and Avidin/
Biotin block was performed according to the manufacturer’s
recommendations (Vector Laboratories). Endogenous immunoglobu-
lins block and primary and secondary antibody incubations were
performed using the M.O.M. kit following the manufacturer’s
recommendations (Vector Laboratories). Anti-BrdU antibody was
incubated for 16 h at 4 8C in a humidiﬁed chamber. Color was
developed using the DAB peroxidase substrate kit (Vector Labora-
tories) followed with hematoxylin staining and dehydration of the
tissues. Nuclei from well-oriented crypts in Atoh1
wt and Atoh1
Dintestine
colons were counted at 403 magniﬁcation, followed by counts of
BrdU-positive cells. The percent of BrdU-positive Atoh1
wt or Atoh1-
null cells was determined for each animal (at least 1,000 cells per
genotype were counted for each animal). Student two-tailed t-test was
performed to measure signiﬁcance. Cleaved caspase-3 staining and
counting were performed similarly to BrdU staining and analysis.
Polyclonal rabbit anti–cleaved caspase-3 antibodies (1:100) were
obtained from Cell Signaling Technology. The Rabbit IgG VECTAS-
TAIN ABC kit was used according to the manufacturer’s recom-
mendations for blocking, antibody incubations, and signal
ampliﬁcation (Vector Laboratories).
Crypt preps. Crypts from wild-type and Atoh1
Dintestine mice were
isolated using a modiﬁcation of the Evans method [47,48]. Mice were
sacriﬁced and the colons removed and ﬂushed with ice-cold PBS,
opened ﬂat, and then placed in cold PBS containing protease and
phosphatase inhibitors. After a brief vortexing, the colon was cut into
four pieces and placed into a 15-ml tube containing shaking solution
(1.5 mM KCL, 96 mM NaCl, 27 mM Na Citrate, 8 mM KH2PO4, 5.6 mM
Na2HPO4, 15 mM EDTA, and 1 mM dithiothreitol supplemented with
protease and phosphatase inhibitors). The tubes were agitated at 4 8C
on a vortexer holding the tubes at 1808 until the solution appeared
cloudy (5–8 min). The colon pieces were transferred into new tubes
with shaking buffer and agitated until most of the crypts were
released (enrichment was assessed by phase contrast microscopy at
different time points). The solution containing the crypts was ﬁltered
through a 100-lm cell strainer to isolate the crypts, and sorbitol (2%
ﬁnal concentration) was slowly added and mixed immediately. The
solution was centrifuged at 160g for 8 min at 4 8C. The supernatant
(containing single cells) was removed, and the pellet (containing
puriﬁed crypts) was snap frozen in liquid nitrogen, to be used for
protein and RNA analyses.
Quantitative reverse-transcriptase polymerase chain reaction. RNA
w a sp u r i ﬁ e df r o mc o l o nc r y p t si s o l a t e df r o mw i l d - t y p ea n d
Atoh1
Dintestine mice using Trizol (Invitrogen) according to the
manufacturer’s recommendations. Trizol-puriﬁed RNA (100 lg) was
subjected to DNase digestion and further puriﬁcation (RNeasy Mini;
Qiagen); 2 lg of total RNA was reverse transcribed (Superscript III,
Invitrogen), and cDNA equivalent to 100 ng of RNA used for SYBR
Green–based real-time PCR using an Mx3005 (Stratagene). For each
gene assessed, colon crypt RNA from nine wild-type and eight
Atoh1
Dintestine mice was compared using the standard curve method of
relative quantiﬁcation. All gene expression levels were normalized to
the expression of GAPDH. t-Tests measured signiﬁcant differences
between the average normalized expression levels in wild-type versus
Atoh1
Dintestine mice.
Whole-tissue/polyp preparations. Cecal and colonic tissues from
wild-type and Atoh1Dintestine mice were homogenized in lysis buffer (13
Phosphate Buffered Saline, 1% NP-40, 0.5% sodium deoxycholate,
0.1% SDS, 0.7 mM EDTA supplemented with protease and
phosphatase inhibitors), sonicated, and the lysates used for quanti-
tation and western blots. Similarly, lysates of colonic tissues and
polyps from APC
min, and APC
min; Atoh1
Dintestine double-mutant mice
were used for whole lysate preparation and western blots. The
following antibodies were used for western blot analysis: p21
waf1
mouse monoclonal antibody (1:500, cat #556431; BD Pharmingen),
actin mouse IgM antibodies (1:100, JLA20; Developmental Studies
Hybridoma Bank), mouse monoclonal p27
kip1 antibody (1:250, cat
#610241; BD Transduction Laboratories), goat anti-p57 polyclonal
antibodies (1:100, cat # sc-1039; Santa Cruz Biotechnology), rabbit
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Biotechnology), and pJNK antibody (1:1000, cat #559309; EMD-
Calbiochem).
pJNK IHC. Formalin-ﬁxed tissues from AOM-treated mice were
used for phosphorylated-JNK (pJNK) immunohistochemistry. Rabbit
polyclonal pJNK antibody was used (1:100, cat #559309; EMD-
Calbiochem). The sections were de-parafﬁnized, hydrated, and the
antigen retrieval was performed in citric acid buffer using a
microwave. Endogenous peroxidase activity was blocked with hydro-
gen peroxide/methanol solution, a short remobilization step was
included (0.2% Triton X 100 in PBS), and Avidin/Biotin block was
performed according to the manufacturer’s recommendations
(Vector Laboratories). The Rabbit IgG VECTASTAIN ABC kit was
used according to the manufacturer’s recommendations for blocking
and antibody incubations (Vector Laboratories). Primary antibody
was incubated at 4 8C for 14–16 h; color was developed using the DAB
peroxidase substrate kit (Vector Laboratories) followed by hematox-
ylin staining and coverslipping. Cells of well-oriented crypts in wild-
type and Atoh1
Dintestine colons were counted at 403 magniﬁcations,
followed by counts of pJNK-positive cells. The total number of cells
and pJNK-positive cell numbers were added for each animal, and the
average numbers were compared across crypts and animals. A
Student t-test was performed to measure signiﬁcance.
Cell culture. MCC cell lines were cultured in RPMI medium
supplemented with 15% FCS (Perbio). The Ht29 cell lines (obtained
from Deutsche Sammlung von Mikroorganismen und Zellkulturen
[DSMZ]) were cultured in McCoy medium supplemented with 10%
FCS. Primary human keratinocytes were isolated and pooled from
foreskins of three different donors (less than 6 y). Fourth passage cells
were used in the experiments. The procedure has been approved by
the ethical committee of the University of Leuven. Experiments
performed adhered to the Declaration of Helsinki Principles.
Keratinocytes were seeded in serum-free and growth factor–contain-
ing medium (Keratinocyte-SFM; Invitrogen), which contains several
growth factors (5 lg/ml insulin, 74 ng/ml hydrocortisone, 6.7 ng/ml
triiodo-L-thyronine, 50 lg/ml bovine pituitary extract, and 5 ng/ml
human recombinant EGF). All culture experiments were done at 37
8Ci n5 %C O 2.
Doubling time. A ﬁxed amount of cells was seeded in standard
culture conditions, and the number of cells was counted after 3 to 5 d.
The doubling times (T
2X) were calculated using the formula T
2X ¼
LN(2)/((LN(nDt)-LN(n0))/Dt) with Dt, time in culture, n0, number of
seeded cells, and nDt the number of cells after Dt
Lentiviral vectors. The lentiviral vector HIV-CMV-Atoh1-IRES-
GFP was constructed by cloning a PCR fragment of Atoh1-IRES into
the HIV-CMV-GFP vector [49], which was used as control vector. The
HIV-CMV-GFP vector was ﬁrst restricted with XbaI and Age1, and
ligated to the Atoh1-IRES fragment, which was spanned between
Xba1 and Age1. The Atoh1 and GFP were expressed from a
bicistronic vector under the control of the CMV promoter. These
lentiviral vectors were produced as described in [50,51]. Stable cell
lines were created by transducing the cells in normal medium,
supplemented with 8 nM polybrene and a multiplicity of infection
between 100 and 150). Four stable cell lines were made with the
lentiviral vectors expressing Atoh1 and eGFP from a bicistronic
Atoh1-IRES-eGFP construct (MCC14.2-Atoh1.1a, MCC14.2-Atoh1.1b,
MCC14.2-Atoh1.2a, and MCC14.2-Atoh1.2b), and one with eGFP
alone (MCC14.2-GFP) as a negative control, under the control of a
CMV promoter (Figure 5A). We failed to created stable cell lines from
the Ht29. Cells were heavily selected against, and FACS isolation did
not yield surviving cells.
Colony formation in soft agar. A total of 2,500 cells/ml were
resuspended in 0.6% agarose (Invitrogen) in culture medium. A 2-ml
layer of 0.35% agarose in culture medium was added on top of the 2-
ml 0.6% layer. After 1 wk, 2 ml of 0.35% agarose in culture medium
was added. Cells were cultured for 2 wk in standard conditions, and
the number of colonies was analyzed under an inverted microscope
with a 103 magniﬁcation. The experiment was done in triplicate.
Cell cycle distribution and progression. Cells were grown up to
40% conﬂuency under standard conditions and were trypsinized.
Cells were ﬁxed and permeabilized using 70% ice-cold ethanol for 2
h. Cells were washed in PBS, and cells were stained for 30 min using
0.1% (v/v) Triton X-100 (Sigma) in PBS and 0.2 mg/ml DNase-free
Rnase A (Sigma) and 20 lg/ml PI (Sigma). Cells were analyzed on a
FACSCalibur cytometer (BectonDickinson). To analyze the cell cycle
progression, cells were pulsed for 20 min with 10 lM BrdU (Sigma).
Medium was then substituted with normal medium for 6 h. Cells were
collected and ﬁxed in 70% ice-cold ethanol. DNA was denatured
using 2 M HCl for 20 min. Cells were stained using anti-BrdU and
IgG-alexa555 and analyzed in a FACSCalibur (BD Bioscience).
Apoptosis detection. Annexin-V staining was performed using
Annexin-V-biotin (Roche) and streptavidin-PercP (BD biosciences) as
described by the manufacturer. Cells were imaged with the Leica TCS
Sp2 confocal microscope, and images were analyzed and quantiﬁed
using LCS software.
Western blotting. Lysates were obtained by scraping cells in
medium and centrifuging the medium. The pellet was resuspended in
lysis buffer containing PBS with 1 mM EDTA, 1 mM EGTA, 50 mM
NaF, 1% TritonX, 5 mM Na3VO4,2 0lM PAO, and Complete Protease
Inhibitor. The crude extract was separated by SDS-PAGE in a 4%–
12% NuPAGE novex bis-tris gel (Invitrogen) and electroblotted onto
Hybond-ECL membrane (Amersham). Antibodies were diluted in the
appropriate concentrations in 5% BSA in TBS-tween20. The
antibodies used are beta-actin (clone AC-15; Sigma), anti–cleaved
caspase-3 (Asp-175; Cell Signaling Technology), polyclonal antibody
to caspase-9(active) (ALEXIS), chromogranin AþB (Abcam), cyclinA1
(Santa Cruz Biotechnology), pJNK (Thr183/Tyr185; BioSource), p27
(BD Bioscience), p21
waf1 (DCS60; Cell Signaling Technology), PCNA
(clone PC10; Sigma), TRK (Santa Cruz Biotechnology), Atoh1 (1/50;
Developmental Studies Hybridoma Bank), NT3 (Santa Cruz Bio-
technology), and Cleaved Notch (Val1744; Cell Signaling Technology).
All western blot analyses are quantiﬁed in Figure S11.
Tyrosine kinase inhibitor, SAPK inhibitor II, and c-secretase
inhibitor. K252a diluted in DMSO, from VWR, and DMSO as control
were used. Final concentrations ranged from 0 lM to 0.5 lM; when no
concentration is mentioned, 0.33 lM was used. SAPK inhibitor II,
from Calbiochem, was used at a concentration of 10 lM. We used
inhibitor X as a c-secretase inhibitor (Calbiochem). Concentrations
used are mentioned in the ﬁgure legend.
RT-PCR and qPCR. mRNA was ampliﬁed using the Superscript II
One-Step RT-PCR system with Platinum Taq-100 reactions (Invitro-
gen) and the ATOH1 primers CAGCCAGTGCAGGAGGAAAA and
GAAAATTCCCCGTCGCTTCT, and the Hes1 primers GGA-
CATTCTGGAAATGACAGTGAA and AGCGCAGCCGTCATCTG,
according to the manufacturer’s protocol. Quantitative RT-PCR was
performed on a ABI prism 7000 (Applied Biosystems). The primers
were designed using Primer Express (Applied Biosystems). The
primers used are ATOH1: CAGCCAGTGCAGGAGGAAAA and
GAAAATTCCCCGTCGCTTCT; Atoh1: GCTGTGCAAGCTGAAGGG
and TCTTGTCGTTGTTGAAGG. Primers to check copy number of
the ATOH1 locus: ATOH1 locus set 1: CCCCGGGAGCAATCTTG and
GGGACCGAGGCGAAGTT; control locus set 1: TCTGGGACCT-
GAGCTAATGGA and GGCCATAATTAGGACCATGAAAGA; and
ATOH1 locus set 2: GCCAGTGCAGGAGGAAAACA and
GAAAATTCCCCGTCGCTTCT. Control locus set 2:
GGGTTCAGCCTCAACTTGTATCC and CCCACCACCTGG-
CATCTCT.
The 90 kinase RT-PCR assay. RNA was diluted to 300 lg/ll and
treated with TURBO DNA-free (Ambion) following the manufac-
turer’s protocol. cDNA was synthesized using random primers and
SuperscriptII reverse transcription (Invitrogen) using the manufac-
turer’s protocol. cDNA was ampliﬁed using gene-speciﬁc primers
(concentration 5 lM) for the different human tyrosine kinases.
Methylation detection. Methylation of the DNA was detected using
ApaI enzyme. DNA (2 lg) was dissolved in 50 ll of the appropriate
buffer and 10 U of ApaI, and incubated at 30 8C overnight. A mirror
condition was done in which the ApaI was exchanged by glycerol as a
control for unspeciﬁc degradation. The resulting DNA was analyzed
using two primer sets: one set spanning the restriction site
(AATAAGACGTTGCAGAAGAG and TCGCAGAGCAAAAAT-
TAAAGGGTGC) and another set next to the restriction site
(CCCCGGGAGCATCTTGCAGCCA and TCGCAGAGCAAAAAT-
TAAAGGGTGC).
Pull-down of methylated DNA fragments (restricted using EcoRI)
was performed using the Methylcollector kit (Active Motif), and
bisulﬁte modiﬁcation of DNA was done using the EZ DNA
Methylation-Gold kit (Zymo Research) according to the manufac-
turers’ protocols.
Array CGH. We carried out array CGH using Code Linked Slides
(AP Biotech) containing the 3,527 BAC clones from the Wellcome
Trust Sanger Institute 1 Mb Clone Set, a gift from N. P. Carter (The
Wellcome Trust Sanger Institute). Array CGH was performed as
described [17].
Sequencing. The ATOH1 open reading frame was ampliﬁed with
PCR using AATAAGACGTTGCAGAAGAG and TCGCAGAG-
CAAAAATTAAAGGGTGC and AmpliTaq Gold DNA polymerase
and the GeneAmp PCR System 2400 (Applied Biosystems). The PCR
products were puriﬁed and sequenced in both directions on the ABI
Prism BigDye (Terminator Cycle Sequencing Kit version 1.1) on an
ABI PRISM 3100 Genetic Analyser (Applied Biosystems).
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Figure S1. Gut-Associated Lymphoid Tissues in AOM-Treated Atoh1
wt
Mice
The colons of AOM-treated Atoh1
wt mice showed large GALT that
were macroscopically counted as polyps; shown is 53magniﬁcation of
representative colonic GALTs. GALT indicated by an arrow.
Found at doi:10.1371/journal.pbio.1000039.sg001 (726 KB PDF).
Figure S2. Histology of Polyps in APC
min Background
(A) Polyps in the APC
min background still have goblet cells, indicating
that Atoh1 is still active.
(B) The polyps in the APC
min; Atoh1
Dintestine mice originate in Atoh1
mutant tissue as seen by the absence of goblet cells.
Found at doi:10.1371/journal.pbio.1000039.sg002 (4.70 MB PDF).
Figure S3. Representative Normal-Appearing Crypts in AOM-
Treated Atoh1
wt and Atoh1
Dintestine Colons
AOM-treated colon sections with well-oriented crypts were used for
BrdU and cleaved caspase-3 (c-Caspase 3) counting. The genotypes of
the representative slides are indicated on the left side of the ﬁgure.
The speciﬁc stain is identiﬁed at the top part of the ﬁgure. Atoh1
wt
(WT) crypts were distinguished from Atoh1-null crypts by the lack of
the secretory goblet cells in the null crypts.
(A–C) Hematoxylin and eosin (H & E) staining of Atoh1
wt crypts in
Atoh1
wt mice (A); and nondeleted Atoh1
wt (B) and Atoh1-null (C) in
Atoh1Dintestine mice.
(D–F) Representative BrdU staining of normal-appearing crypts in
Atoh1
wt mice (D) and nondeleted Atoh1
wt (E) and Atoh1-null (F) in
Atoh1
Dintestine mice.
(G–I) Representative cleaved caspase-3 staining of normal-appearing
crypts in Atoh1
wt mice (G); and nondeleted Atoh1
wt (H) and Atoh1-null
(I) in Atoh1
Dintestine mice. Arrows point to positive cells at the surface of
the crypts. The images were captured at 203 magniﬁcation.
Found at doi:10.1371/journal.pbio.1000039.sg003 (4.96 MB PDF).
Figure S4. ATOH1 Expression Correlates with Population Doubling
Time
(A) ATOH1 mRNA transcripts in ﬁve independent MCC cell lines. The
name of the cell line is indicated above each lane. RT-PCR was done
with 100 ng of RNA under nonsaturating conditions.
(B) Doubling times in hours of the ﬁve MCC cell lines. Error bars
indicate the standard deviation.
(C) RT-qPCR for ATOH1 in MCC1 and MCC14.2 cell lines. ATOH1
mRNA levels standardized to GADPH mRNA levels.
Found at doi:10.1371/journal.pbio.1000039.sg004 (760 KB PDF).
Figure S5. Summary Table of All Patient Data
First column indicates patient numbers. Next, the relative ratios for
ATOH1 genomic DNA (gDNA) over control locus is presented for
each of the two primer sets as analyzed by qPCR. The next two
columns indicate the classiﬁcation of the deletion/duplication status
of the ATOH1 locus. The mRNA expression is shown relative to
control colon samples, with next to it, the classiﬁcation of the
expression. Clinical data are given in the third panel, namely cancer
stage and metastasis. In the last panel, methylation of the ATOH1
locus is shown using three different methods.
Found at doi:10.1371/journal.pbio.1000039.sg005 (760 KB PDF).
Figure S6. Array CGH Analysis of Three Patient Samples, Demon-
strating No Aberration of the ATOH1 Locus
Each bar represents the log2 of the value for affected individuals (ind)
versus a control sample (reference) for each probe, ordered based on
the probes’ chromosomal location. The region between 131 Mb and
141 Mb is shaded. The location of the ATOH1 locus is shown with an
arrow. The abnormalities were conﬁrmed by dye swap experiments.
Found at doi:10.1371/journal.pbio.1000039.sg006 (4.55 MB PDF).
Figure S7. Methylation of the ATOH1 Locus
(A) Schematic representation of ATOH1 locus. The white box indicate
the ATOH1 ORF, and the gray box the position of the CpG island. The
primers are indicated as arrows.
(B) Detection of methylation at the ATOH1 locus using the ApaI
methylation-sensitive restriction enzyme. PCR fragments generated
using primers spanning the ApaI restriction site from ApaI restricted
genomic DNA; presence of a band indicates methylation of the
ATOH1 CpG island.
(C) Detection of methylation using methylation-sensitive PCR: upon
bisulﬁte modiﬁcation, presence of a band indicates methylation of
the ATOH1 CpG island.
Found at doi:10.1371/journal.pbio.1000039.sg007 (159 KB PDF).
Figure S8. Atoh1 Binds the Dnmt Proteins and Associates to a DNA
Methyltransferase Activity
(A) GST Pull-down assays using Atoh1 protein fused to GST (GST-
Atoh1) and in vitro translated Dnmts (IVT-Dnmt1, IVT-Dnmt3a, or
IVT-Dnmt3b).
(B) A GST-fused Atoh1 protein was used to purify DNA methyl-
transferase activity from nuclear extracts. After incubation, the beads
were washed and assayed for DNA methyltransferase activity read as
c.p.m. of S-adenosyl-L[methyl-3H] methionine incorporated into an
oligonucleotide substrate. GST-tagged embryonic ectoderm develop-
ment protein (GST-EED) was used as a positive control.
(C) Coimmunoprecipitation experiments shows that Atoh1 associated
with Dnmt1. The 293T cells were transiently transfected in culture
dishes (10-cm diameter) with 3 lg of HA-Atoh1 plasmid
(D) Mapping of Atoh1 binding to Dnmt1. GST Pull-downs were
performed with Dnmt1 fragments fused to GST and in vitro–
translated Atoh1. The upper part is a schematic representation of the
Dnmt1 sequences used.
Found at doi:10.1371/journal.pbio.1000039.sg008 (1.04 MB PDF).
Figure S9. Immunohistochemical Analysis of Phosphorylated JNK in
Atoh1
Dintestine and Atoh1
wt Mice
(A) Representative pJNK1/2 staining in Atoh1
wt crypt (dashed white
line). The arrows indicate pJNK-positive cells.
(B) pJNK-positive cells (arrows) in wild-type (dashed gray line) and
Atoh1-null (dashed black line) crypts in Atoh1
Dintestine mice.
(C) Bar graph showing the percentage of pJNK-positive cells in wild-
type mice (white); and wild-type (gray) and Atoh1-null crypts in
Atoh1
Dintestine mice. Error bars indicate the standard error of the mean.
No signiﬁcant differences between genotypes were detected.
Found at doi:10.1371/journal.pbio.1000039.sg009 (4.18 MB PDF).
Figure S10. ATOH1 Interacts with the Cell Cycle and Apoptosis
(A) Cell cycle distribution of MCC14.2-derived cell lines without
(MCC14.2 and MCC14.2-GFP) and with Atoh1 expression (MCC14.2-
Atoh1.1a and MCC14.2-Atoh1.2a). No signiﬁcant change in distribu-
tion throughout the cell cycle can be observed.
(B) Maximal projection image of AnnexinV staining (red) on cells
transduced with lentiviral vectors expressing GFP (left panel) or
Atoh1-IRES-GFP (right panel). GFP is in green.
(C) Western blot analysis for CyclinA1, PCNA, p27
kip, c-myc, phospho-
H3 and p21
waf1 of lysates of MCC14.2 cells, MCC14.2-GFP and two
MCC14.2 cell lines transduced with Atoh1-IRES-eGFP (MCC14.2-
Atoh1.1a and MCC14.2-Atoh1.2a). The corresponding actin loading
controls are shown under each blot.
(D–H) Quantiﬁcation of expression levels of cyclinA1 (D), PCNA (E),
p27 (F), c-myc (G), and phospho-histoneH3. (H) Representative blots
are shown in (C).
Found at doi:10.1371/journal.pbio.1000039.sg010 (2.90 MB PDF).
Figure S11. ATOH1 Acts Independently of Notch but Modulates RTK
Expression
(A) RT-PCR for target of Notch signaling HES1 on mRNA isolated
from MCC14.2 cells, MCC14.2 cells transduced with GFP, and two
MCC14.2 cell lines transduced with Atoh1-IRES-eGFP (MCC14.2-
Atoh1.1a and MCC14.2-Atoh1.2a). GADPH loading control is shown
below.
(B) Western blot analysis for cleaved intracellular Notch (NICD).
Different concentrations of presinilin inhibitor X were used; a plus
sign (þ) indicates a positive control for cleaved NICD.
(C) Different concentrations of c-secretase inhibitor (inhibitor X) on
MCC14.2 do not inﬂuence the proliferation rate. First lane: 10 lM
inhibitor X, second lane: DMSO control of previous lane, third lane: 1
lM inhibitor X, fourth lane: DMSO control of previous lane, and ﬁfth
lane: untreated.
(D) RT-PCR for expression of 90 tyrosine kinases scored from
undetectable (white) over orange (expression) to red (strong expres-
sion) on mRNA or on untransduced MCC14.2 cells (lane 1), GFP
transduced MCC14.2 cell line (lane 2), and two independent MCC14.2-
derived cell lines transduced with Atoh1-IRES-eGFP vectors (lane 3:
MCC14.2-Atoh1.2a) and on untransfected HT29 cells (lane14: HT29),
GFP-transfected HT29 cells (lane5: HT29-GFP), and HT29 cells
transfected with the Atoh1-IRES-eGFP construct (lane 6: HT29-Atoh1).
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levels) in MCC cell lines. MCC1 (ﬁrst lane: MCC cell line with
endogenous high ATOH1 expression), MCC14.2 (lane 2), GFP-
transduced MCC14.2 cell line (lane 3), and two independently made
MCC14.2-derived cell lines transduced with Atoh1-IRES-GFP vectors
(lane 4: MCC14.2-Atoh1.1a, and lane 5: MCC14.2-Atoh1.2a).
(F) Western blot analysis for NTRK1 and Neurotrophin-3 (NT3) of
untransduced MCC14.2 cells (lane 1), GFP-transduced MCC14.2 cell
line (lane 2), and two independently made MCC14.2-derived cell lines
transduced with Atoh1-IRES-GFP vectors (lane 3: MCC14.2-Atoh1.1a,
and lane 4: MCC14.2-Atoh1.2a); actin loading controls are repre-
sented below each blot.
(G and H) Quantiﬁcations of western blots in (F), normalized to actin.
Found at doi:10.1371/journal.pbio.1000039.sg011 (2.04 MB PDF).
Figure S12. Quantiﬁcations of Western Blot Analysis in Main Figures
(Minimum of Two Blots per Quantiﬁcation)
The quantiﬁcations are performed with USI software. The signal for
the protein of interest was standardized to its respective actin loading
control. Antibody is stated above each graph, representative experi-
ments are shown in main ﬁgures: (A) Figure 4B, (B) Figure 4B, (C)
Figure 4B, (D1) Figure 4C, (D19) Figure 4C, (D2) Figure 4C, (D29)
Figure 4C, (E) Figure 5B , (F) Figure 5B, (G) Figure 6A, (H) Figure 6A,
(I) Figure 6A, ( J) Figure 6A, (K) Figure 6B, (L) Figure 6B, (M) Figure
6B, (N) Figure 6B, (O) Figure 6C, (P) Figure 6C, (Q) Figure 6C, (R)
Figure 6E, (S) Figure 6E, (T) Figure 6E, (U) Figure 7D, (V) Figure 7D,
(W) Figure 7E, (X) Figure 7E, and (Y) Figure 7E.
Found at doi:10.1371/journal.pbio.1000039.sg012 (365 KB PDF).
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